ClinicalTrials.gg
CompletedNCT00391443BUILD 3Updated Feb 4, 2025Results posted

BUILD 3: Bosentan Use in Interstitial Lung Disease

A Phase 3 interventional study of Bosentan and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
616
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • BUILD 3
  • Idiopathic Pulmonary Fibrosis
  • Tracleer
  • Interstitial Lung Disease
  • bosentan
  • Actelion
03

In context

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

This study's enrollment of 616 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male or female aged 18 years or older (females of must have been surgically sterilized or use a reliable method of .)
  • Proven diagnosis of IPF according to American Thoracic Society / European Respiratory Society (ATS-ERS) statement, of \<3 years, with surgical lung (SLB)

Exclusion criteria

Exclusion Criteria:

  • Interstitial lung disease due to conditions other than IPF.
  • Presence of extensive honeycombing (HC) on baseline high-resolution computed tomography (HRCT) scan.
  • Severe concomitant illness limiting (\<1 year).
  • Severe restrictive lung disease.
  • Obstructive lung disease.
  • Diffusing capacity of the lung for carbon monoxide \<30% predicted.
  • Residual volume > or = 120% predicted.
  • Documented sustained improvement of patient's IPF condition up to 12 months prior to randomization with or without IPF-specific therapy.
  • Recent pulmonary or upper respiratory tract infection (up to 4 weeks prior to randomization).
  • Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements.
  • Chronic heart failure with (NYHA) class III/IV or known \<25%.
  • (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) > 1.5 times the ranges.
  • Moderate to severe hepatic impairment.
  • Serum creatinine > or = 2.5 mg/dl or chronic dialysis.
  • concentration \<75% the lower limit of the normal ranges.
  • Systolic blood pressure \<85 mmHg.
  • Pregnancy or breast-feeding.
  • Current drug or alcohol dependence.
  • Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of randomization):oral (>20 mg/day of prednisone or equivalent), or cytotoxic drugs, antifibrotic drugs, chronic use of N-acetylcysteine (prescribed for IPF).
  • Oral anticoagulants other than those indicated for a venous or arterial thrombotic disease.
  • Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A, tacrolimus) up to 1 week prior to randomization.
  • Treatment with an endothelin receptor antagonist up to 3 months prior to randomization.
  • Participation in the BUILD 1 trial.
  • Treatment with another drug up to 3 months prior to randomization or planned treatment.
  • Known to bosentan or any of the .
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
616 participants (actual)

Study arms

  • Experimental
    Bosentan

    Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg b.i.d. (if body weight \< 40 kg)

    Drug: Bosentan

  • Placebo comparator
    Placebo

    Subjects receive placebo matching the bosentan treatment regimen

    Drug: Placebo

Interventions

  • Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)

    Also known as: Ro 47-0203, ACT-050088

  • DrugPlacebo

    Placebo matching bosentan 62.5 mg tablets and 125 mg tablets

06

What researchers measure

Primary outcomes

  1. Time to Occurrence of Disease Worsening or Death up to End of Study.

    Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).

    Time frame: 36 months

Secondary outcomes

  1. Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.

    Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).

    Time frame: 12 months

07

Results

Posted May 25, 2012

Participant flow

Participant flow — Overall Study
MilestonePlaceboBosentan
Started209407
Completed209407
Not completed00

Outcome measures

PrimaryTime to Occurrence of Disease Worsening or Death up to End of Study.

Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).

Time frame:
36 months
Reported as:
Number · participants with event
Time to Occurrence of Disease Worsening or Death up to End of Study.
participants with eventPlaceboBosentan
month 4 (122 days)1018
month 8 (244 days)2240
month12 (366 days)4374
month 18 (549 days)74117
month 24 (732 days)88145
month 30 (915 days)94156
month 36 (1098 days)94158
Statistical analysis
  • Placebo vs Bosentan · Log Rank · p = 0.2110 · Hazard ratio (hr): 0.850 · 95% CI 0.658 to 1.097
SecondaryPercentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.

Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).

Time frame:
12 months
Reported as:
Number · percentage of participants with event
Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.
percentage of participants with eventPlaceboBosentan
Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.23.9 (18.3 to 30.3)19.9 (16.1 to 24.1)
Statistical analysis
  • Placebo vs Bosentan · Fisher Exact · p = 0.2542 · Relative risk reduction: 0.17 · 95% CI -0.13 to 0.39

Adverse events

Collected over All treatment-emergent adverse events occurring after the start of study treatment and within 24 hours after the end of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—74/209 (35.4%)200/209 (95.7%)
Bosentan—129/406 (31.8%)386/406 (95.1%)
Most frequent serious events
Showing 10 of 142
Most frequent serious events
EventPlaceboBosentan
IDIOPATHIC PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders17/20941/406
PNEUMONIAInfections and infestations10/20916/406
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations5/2097/406
ANGINA PECTORISCardiac disorders4/2090/406
DYSPNOEARespiratory, thoracic and mediastinal disorders0/2096/406
CORONARY ARTERY DISEASECardiac disorders1/2096/406
BRONCHITISInfections and infestations3/2092/406
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/2090/406
CARDIAC FAILURE CONGESTIVECardiac disorders3/2091/406
BACK PAINMusculoskeletal and connective tissue disorders3/2093/406
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboBosentan
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations59/209114/406
IDIOPATHIC PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders59/20992/406
COUGHRespiratory, thoracic and mediastinal disorders51/20978/406
DYSPNOEARespiratory, thoracic and mediastinal disorders24/20957/406
BRONCHITISInfections and infestations28/20944/406
FATIGUEGeneral disorders15/20946/406
OEDEMA PERIPHERALGeneral disorders23/20937/406
HEADACHENervous system disorders22/20944/406
NASOPHARYNGITISInfections and infestations22/20940/406
SINUSITISInfections and infestations18/20938/406

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBosentanTotal
Mean63.2 ± 9.163.8 ± 8.463.6 ± 8.6
Age, Customized
Age, Customized(participants)PlaceboBosentanTotal
Between 18 and 40 years459
Between 41 and 60 years74119193
Between 61 and 70 years87195282
> 70 years4488132
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBosentanTotal
Female76111187
Male133296429
Region of Enrollment
Region of Enrollment(participants)PlaceboBosentanTotal
United States99185284
Serbia202
Spain71522
Ireland224
Austria347
Israel71623
Switzerland5813
Italy81422
United Kingdom3710
France91423
Czech Republic5914
Canada143044
Belgium123
Croatia022
Australia112233
Germany102636
Netherlands022
Japan142640
Korea, Republic of92332
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9. doi: 10.1164/rccm.201011-1874OC. Epub 2011 Apr 7. PubMed 21474646 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Feb 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 2 years 3 months after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2006
First posted
Oct 24, 2006
Start
Feb 2007
Primary completionActual
Feb 2010
CompletionActual
Jul 2010
Results delay requested
Feb 11, 2010
Results first posted
May 25, 2012
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00391443
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Oct 24, 2006
Start date
Feb 2007
Primary completion
Feb 2010
Completion
Jul 2010
Results posted
May 25, 2012
Last update
Feb 4, 2025

Study contacts

Isabelle Leconte
study director · Actelion
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion